Pancreatic Lipase Antibody (PNLIP/9042) [DyLight 755]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-26991IR
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Immunohistochemistry-Paraffin
Label
DyLight 755 (Excitation = 754 nm, Emission = 776 nm)
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # PNLIP/9042
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant fragment (around aa 1-200) of human Pancreatic Lipase protein (exact sequence is proprietary)
Localization
Secreted
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Applications for Pancreatic Lipase Antibody (PNLIP/9042) [DyLight 755]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Pancreatic Lipase
Long Name
Pancreatic triacylglycerol lipase
Alternate Names
PNLIP, PTL
Gene Symbol
PNLIP
Additional Pancreatic Lipase Products
Product Documents for Pancreatic Lipase Antibody (PNLIP/9042) [DyLight 755]
Product Specific Notices for Pancreatic Lipase Antibody (PNLIP/9042) [DyLight 755]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...